CO6331431A2 - Derivados de tiofeno o tiazol y su uso como inhibidores de p13k - Google Patents

Derivados de tiofeno o tiazol y su uso como inhibidores de p13k

Info

Publication number
CO6331431A2
CO6331431A2 CO10161488A CO10161488A CO6331431A2 CO 6331431 A2 CO6331431 A2 CO 6331431A2 CO 10161488 A CO10161488 A CO 10161488A CO 10161488 A CO10161488 A CO 10161488A CO 6331431 A2 CO6331431 A2 CO 6331431A2
Authority
CO
Colombia
Prior art keywords
inhibitors
tiazol
thiophen
derivatives
compounds
Prior art date
Application number
CO10161488A
Other languages
English (en)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul David Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6331431(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CO6331431A2 publication Critical patent/CO6331431A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I:en donde R1, R2, CY, Y1, Y2, X1, X2, y X3 son como se describen en la especificación. Los compuestos son inhibidores de PI3K y son de este modo útiles para tratar trastornos proliferativos, inflamatorios o cardiovasculares.
CO10161488A 2008-06-19 2010-12-23 Derivados de tiofeno o tiazol y su uso como inhibidores de p13k CO6331431A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
CO6331431A2 true CO6331431A2 (es) 2011-10-20

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10161488A CO6331431A2 (es) 2008-06-19 2010-12-23 Derivados de tiofeno o tiazol y su uso como inhibidores de p13k

Country Status (21)

Country Link
US (3) US8183240B2 (es)
EP (1) EP2313399B1 (es)
JP (1) JP5596026B2 (es)
KR (1) KR20110018451A (es)
CN (1) CN102066365A (es)
AU (1) AU2009260782B2 (es)
BR (1) BRPI0914223A2 (es)
CA (1) CA2727069A1 (es)
CL (1) CL2010001474A1 (es)
CO (1) CO6331431A2 (es)
CR (1) CR20110032A (es)
EA (1) EA201170052A1 (es)
ES (1) ES2491522T3 (es)
GE (1) GEP20125650B (es)
IL (1) IL210055A0 (es)
MA (1) MA32468B1 (es)
MX (1) MX2010014125A (es)
NZ (1) NZ589844A (es)
UA (1) UA106206C2 (es)
WO (1) WO2009154741A1 (es)
ZA (1) ZA201008875B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
CA2727069A1 (en) * 2008-06-19 2009-12-23 David P. Cardin Thiophene or thiazole derivatives and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) * 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
AU2011289377A1 (en) 2010-08-11 2013-03-07 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
CN103237450A (zh) 2010-10-13 2013-08-07 米伦纽姆医药公司 杂芳基化合物和其用途
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
PL2790705T3 (pl) 2011-12-15 2018-06-29 Novartis Ag Zastosowanie inhibitorów czynności lub funkcji PI3K
EP2793894A4 (en) * 2011-12-23 2015-07-08 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
CN107267554A (zh) 2012-03-14 2017-10-20 萨克生物研究学院 腺病毒肿瘤诊断法
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
KR20160115999A (ko) * 2014-02-14 2016-10-06 더 유니버시티 오브 브리티쉬 콜롬비아 치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CA3144848C (en) 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
TW202138363A (zh) 2019-12-20 2021-10-16 德商拜耳廠股份有限公司 經取代之噻吩甲醯胺及其衍生物（三）
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
CN101031293A (zh) 2004-05-06 2007-09-05 普莱希科公司 Pde4b抑制剂及其应用
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
DE602007007323D1 (de) 2006-04-26 2010-08-05 Hoffmann La Roche Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
EP2207781B1 (en) 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
CA2727069A1 (en) * 2008-06-19 2009-12-23 David P. Cardin Thiophene or thiazole derivatives and their use as pi3k inhibitors

Also Published As

Publication number Publication date
CR20110032A (es) 2011-03-14
US20120202812A1 (en) 2012-08-09
NZ589844A (en) 2012-11-30
ES2491522T3 (es) 2014-09-08
MA32468B1 (fr) 2011-07-03
EP2313399B1 (en) 2014-05-28
US8440664B2 (en) 2013-05-14
CN102066365A (zh) 2011-05-18
WO2009154741A8 (en) 2010-03-25
AU2009260782A1 (en) 2009-12-23
BRPI0914223A2 (pt) 2019-09-24
AU2009260782B2 (en) 2014-12-11
EP2313399A1 (en) 2011-04-27
KR20110018451A (ko) 2011-02-23
JP2011524904A (ja) 2011-09-08
EA201170052A1 (ru) 2011-06-30
US20100075951A1 (en) 2010-03-25
UA106206C2 (ru) 2014-08-11
ZA201008875B (en) 2012-02-29
US8183240B2 (en) 2012-05-22
GEP20125650B (en) 2012-09-25
CA2727069A1 (en) 2009-12-23
US20130217689A1 (en) 2013-08-22
WO2009154741A1 (en) 2009-12-23
JP5596026B2 (ja) 2014-09-24
MX2010014125A (es) 2011-02-24
IL210055A0 (en) 2011-02-28
CL2010001474A1 (es) 2011-04-29

Similar Documents

Publication Publication Date Title
CO6331431A2 (es) Derivados de tiofeno o tiazol y su uso como inhibidores de p13k
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
NI201100048A (es) Aminotriazolopiridinas y su uso como inhibidores de la cinasa.
UY33554A (es) Heteroarilos y usos de los mismos
CO6300942A2 (es) Piridinas y pirazinas como inhibidores de p13k
ECSP11010889A (es) INHIBIDORES DE cMET
DK2240451T3 (da) Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
BRPI0815979A2 (pt) compostos e composições com inibidores de quinase, bem como uso dos mesmos
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
BRPI0908849A2 (pt) Composto e composições como c-kit e inibidores de pdgfr quinase
CL2011002825A1 (es) Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c.
DK2310382T3 (da) Amidophenoxyindazoler, der er anvendelige som hæmmere af c-met
EA201490846A1 (ru) Новые производные арилхинолина
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY32320A (es) Nuevos compuestos de ciclopentanodiona herbicidamente activos, derivados, procesos, composiciones y uso en el control de malas hierbas
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb
ECSP15050110A (es) Derivados de triazina

Legal Events

Date Code Title Description
FG Application granted